Alzheimer’s disease (AD): non-drug management
Evidence-based neurology checklist on alzheimer’s disease (ad): non-drug management: Relaying the diagnosis Deliver the diagnosis with compassion and empathy Ask about diagnosis preference Convey realistic hope Provide practical strategies Provide education and access to high-quality resources…
Relaying the diagnosis
- Deliver the diagnosis with compassion and empathy
- Ask about diagnosis preference
- Convey realistic hope
- Provide practical strategies
- Provide education and access to high-quality resources
- Provide written summary of diagnosis and management plan
Give written information on clinical and social issues
Discuss advanced directives
Assess functional impairments
Non-drug treatments of cognitive dysfunction
References
- A NICE–SCIE Guideline on supporting people with dementia and their carers in health and social care National Clinical Practice Guideline Number 42. November 2006.
- Armstrong MJ, BedenfieldN, Rosselli M, et al. Best practices for communicating a diagnosis of dementia: results of a multi-stakeholder modified Delphi consensus process. Neurol Clin Pract 2024; 14:e200223.
- NICE Guidance NG97: Dementia: assessment, management and support for people living with dementia and their carers. June 2018.
- Hogan DB, Bailey P, Black S, et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ 2008; 179:787-793.
- Galvin JE, Roe CE, Powlishta KK, et al. The AD8: a brief informant interview to detect dementia. Neurology 2005; 65:559-564.
- And 1 more. Subscribe to see the full list
Related checklists
- Alzheimer’s disease (AD): risk factors
- Alzheimer’s disease (AD): protective factors
- Alzheimer’s disease (AD): clinical features
- Alzheimer's Disease (AD) v frontotemporal dementia (FTD)
- Alzheimer’s disease (AD): investigations
- Alzheimer’s disease (AD): emerging investigations
- Alzheimer’s disease (AD): preventative measures
- Alzheimer’s disease (AD): conventional drug treatments
- Alzheimer’s disease (AD): lecanemab treatment
- Alzheimer’s disease (AD): investigational treatments
- Alzheimer’s disease: driving and safety issues